RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
-3.83%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$928M
AUM Growth
+$928M
(-2.2%)
Cap. Flow
+$42.1M
Cap. Flow
% of AUM
4.54%
Top 10 Holdings %
Top 10 Hldgs %
34.27%
Holding
87
New
4
Increased
25
Reduced
17
Closed
2
Top Buys
| 1 |
Eli Lilly
LLY
|
$10.2M |
| 2 |
Charles River Laboratories
CRL
|
$8.62M |
| 3 |
Procept Biorobotics
PRCT
|
$7.02M |
| 4 |
Intuitive Surgical
ISRG
|
$6.87M |
| 5 |
Medtronic
MDT
|
$6.5M |
Top Sells
| 1 |
Cigna
CI
|
$10M |
| 2 |
Zimmer Biomet
ZBH
|
$8.75M |
| 3 |
Elevance Health
ELV
|
$7.84M |
| 4 |
UnitedHealth
UNH
|
$7.06M |
| 5 |
Molina Healthcare
MOH
|
$6.54M |
Sector Composition
| 1 | Healthcare | 99.51% |
| 2 | Industrials | 0.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Danaher
DHR
$143B
| $14.9M | 1.61% |
60,000
| – | – |
|
27
Biogen
BIIB
$20.8B
| $14.5M | 1.57% |
56,500
-8,000
| -12% | -$2.06M |
|
|
AXNX
28
DELISTED
Axonics, Inc. Common Stock
AXNX
| $12.9M | 1.39% |
230,000
| – | – |
|
29
Natera
NTRA
$23B
| $11.8M | 1.27% |
266,769
+66,769
| +33% | +$2.95M |
|
30
Lantheus
LNTH
$3.75B
| $11.7M | 1.26% |
168,000
+68,000
| +68% | +$4.72M |
|
|
IMGN
31
DELISTED
Immunogen Inc
IMGN
| $11.1M | 1.2% |
700,000
-50,000
| -7% | -$794K |
|
32
Exact Sciences
EXAS
$9.33B
| $10.9M | 1.18% |
160,000
-15,000
| -9% | -$1.02M |
|
33
Privia Health
PRVA
$2.84B
| $10.6M | 1.14% |
460,000
| – | – |
|
34
Alkermes
ALKS
$4.95B
| $10.4M | 1.12% |
370,000
+20,000
| +6% | +$560K |
|
35
Dynavax Technologies
DVAX
$1.19B
| $10.3M | 1.11% |
700,000
| – | – |
|
36
IQVIA
IQV
$31.4B
| $9.25M | 1% |
47,000
| – | – |
|
|
37
Charles River Laboratories
CRL
$7.99B
| $8.62M | 0.93% |
+44,000
| New | +$8.62M |
|
38
Alignment Healthcare
ALHC
$3.23B
| $8.33M | 0.9% |
1,200,000
+200,000
| +20% | +$1.39M |
|
39
Apellis Pharmaceuticals
APLS
$3.51B
| $8.18M | 0.88% |
215,000
+25,000
| +13% | +$951K |
|
40
Alnylam Pharmaceuticals
ALNY
$58.6B
| $7.97M | 0.86% |
45,000
| – | – |
|
|
MRTX
41
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $7.62M | 0.82% |
175,000
+35,000
| +25% | +$1.52M |
|
|
42
Zimmer Biomet
ZBH
$20.8B
| $6.73M | 0.73% |
60,000
-78,000
| -57% | -$8.75M |
|
43
Immunovant
IMVT
$2.91B
| $6.38M | 0.69% |
166,061
+66,061
| +66% | +$2.54M |
|
44
Neurocrine Biosciences
NBIX
$13.5B
| $6.14M | 0.66% |
54,566
+14,566
| +36% | +$1.64M |
|
|
KRTX
45
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $5.92M | 0.64% |
35,000
| – | – |
|
46
Cytokinetics
CYTK
$5.98B
| $5.89M | 0.64% |
200,000
| – | – |
|
47
BioNTech
BNTX
$24.1B
| $5.76M | 0.62% |
53,000
-17,000
| -24% | -$1.85M |
|
48
Glaukos
GKOS
$5.42B
| $5.49M | 0.59% |
73,000
-22,000
| -23% | -$1.66M |
|
|
ITCI
49
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $4.95M | 0.53% |
95,000
| – | – |
|
50
Veeva Systems
VEEV
$44.4B
| $4.68M | 0.5% |
23,000
-12,000
| -34% | -$2.44M |
|